anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
In the present invention parapox genomes were screened using a novel expression strategy to test genes for dendritic cell recruitment activity. One gene was identified, designated as B2WL, that induces dendritic cell accumulation when expressed in skin. In additional testing a second gene, PP30, was identified that exhibited adjuvant activity in the absence of stimulating dendritic cell accumulation at the site of inoculation. When co-inoculated with an antigen-encoding plasmid, both genes acted as adjuvants in stimulating an antibody response to antigens. Furthermore, nucleic acids encoding the identified B2WL peptide adjuvant enhanced the level of protection against viral infection provided by immunization with an HA-expression plasmid. Thus, novel adjuvants for genetic immunization are identified. The invention also demonstrates the application of the linear expression element (LEE) technology for screening genomes of pathogens that may contain genes that are useful when expressed and tested in a novel context.
Most research to date in neonatal lung disease has focused on bronchopulmonary dysplasia (BPD) prevention. As a result, insufficient investigation has been performed to define optimal respiratory management strategies for infants and young children with established BPD. Thus, there is no robust evidence base to guide ventilator management to promote lung disease recovery and support neurodevelopment in this population. Neurally adjusted ventilatory assist (NAVA) is an alternative to conventional flow triggered ventilation that has shown promise for improving respiratory gas exchange, patient-ventilator interaction, and work of breathing in preterm neonates. The safety and efficacy of NAVA in infants and young children with established, severe BPD is uncertain. This prospective, unblinded, pilot randomized cross-over trial of 2 modes of mechanical ventilation will compare measures of pulmonary mechanics, respiratory gas exchange, and patient comfort between conventional flow triggered mechanical ventilation and NAVA among 20 prematurely born infants and young children receiving invasive respiratory support for severe BPD.
Over 12 weeks, participants will receive 10 physiotherapy sessions and 15 sham laser sessions, lasting a total of 50 minutes. Laser and physiotherapy treatments will be delivered within the same visit where possible. For the physiotherapy, the therapist will start with education, followed by progressive relaxation exercises and deep breathing. Participants will practice graded pelvic floor muscle (PFM) contractions, manual stretching techniques with external palpation, and gradually progressing to the insertion of one or two fingers into the vagina. Finally, vaginal dilators will be used to stretch the vaginal opening and PFMs. The participant will use relaxation breathing and contraction/relaxation cycles to facilitate insertion, progressing to larger dilators as tolerated. For the sham laser, the same protocol will be followed as described in previous arms.
Physical activity is associated with health benefits. Acute prolonged and strenuous exercise, i.e. Marathon running, leads to hemodynamic, endothelial and myocardial functional changes. Whether these myocardial, endothelial and hemodynamic changes can also develop and persist through repetitive extreme and prolonged physical activity is currently still a matter of controversy. In addition, it is not known whether adaptations and changes over time can develop into clinically relevant cardiovascular events with negative health consequences in healthy athletes. The aim of this study is to detect exercise-induced physiological changes (inter alia of the cardiovascular system) induced by repetitive ultra-endurance strain over a period of 10 years.

For this purpose, 277 male participants from the Be-MaGIC study (Marathon 2009) are examined in this prospective observational study. A single examination with the following components will take place: Anthropometry, clinical examination, laboratory, resting / exercise electrocardiography cardiopulmonary stress test, echocardiography, and fundus camera. Further examinations will be conducted in participants with abnormal examination results in line with current clinical recommendations.
PROBLEM TO BE SOLVED: To obtain a health food scarcely affected by gastric acid and water and effectively exhibiting the intestinal function controlling action by encapsulating a specific oil and fat and a specific valuable bacterium in a specific enteric seam capsule. SOLUTION: This health food is produced by encapsulating (A) an oil and fat having intestinal function controlling action, (B) a valuable bacterium having intestinal function controlling action and optionally (C) a water-absorbing substance (e.g. dried starch) in (D) an enteric seam capsule insoluble in gastric acid and soluble in the intestines. The component A is olive oil, palm oil, cottonseed oil, wheat embryo oil, fish oil, etc., the component B is Lactobacillus acidophilus, Lactobacillus casei, Bifidobacterium longum, etc., and the component D is e.g. a seam capsule made of gelatin and coated with a component suppressing the solubility in gastric acid (e.g. zein) or a seam capsule composed of gelatin containing sodium alginate.
The invention relates to a high-purity ginkgo flavone and a composition thereof. The high-purity ginkgo flavone is light brownish yellow, and tastes slightly bitter; the content of ginkgo flavone is greater than or equal to 50%, the peak ratio of quercetin to kaempferol is 0.8-1.2, the peak ratio of isorhamnetin to quercetin is greater than or equal to 0.15, the concentration of ginkgoic acid is smaller than 5ppm, and the content of residue on ignition is smaller than 0.8%. The water content is smaller than 5.0%. The method for preparing the high-purity ginkgo flavone comprises the following steps: extracting by heating ginkgo leaves, which are used as the raw material, under reflux with a 20-80 wt% ethanol solution; concentrating the extracting solution to recover ethanol; separating by passing through macroporous resin columns; carrying out ethanol desorption; diluting the product by adding water; adsorbing by passing the product through a gel-type hydrogen bond adsorption resin which is mainly based on hydrogen bond adsorption, and desorbing; and collecting the effluent liquid and the desorption liquid, concentrating and drying. The preparation technique is simple and reliable, has the advantage of low cost, and does not use toxic organic solvents in the process, thereby being environment-friendly. The high-purity ginkgo flavone can be made into a composition as an effective constituent, and the composition can be used as various preparations (capsules, tablets, oral liquids, granules, powder, injections and the like) of ginkgo flavone medicines or health products.
Pediatric Patients

A double-blind, randomized, placebo-controlled, parallel-group study was conducted in children aged 6 to 12 (N=584) who met DSM-IV® criteria for ADHD (either the combined type or the hyperactive-impulsive type). Patients were randomized to fixed-dose treatment groups receiving final doses of 10, 20, or 30 mg of ADDERALL XR or placebo once daily in the morning for three weeks. Significant improvements in patient behavior, based upon teacher ratings of attention and hyperactivity, were observed for all ADDERALL XR doses compared to patients who received placebo, for all three weeks, including the first week of treatment, when all ADDERALL XR subjects were receiving a dose of 10 mg/day. Patients who received ADDERALL XR showed behavioral improvements in both morning and afternoon assessments compared to patients on placebo.

In a classroom analogue study, patients (N=51) receiving fixed doses of 10, 20, or 30 mg ADDERALL XR demonstrated statistically significant improvements in teacher-rated behavior and performance measures, compared to patients treated with placebo.

A double-blind, randomized, multicenter, parallel-group, placebo-controlled study was conducted in adolescents aged 13 to 17 (N=327) who met DSM-IV® criteria for ADHD. The primary cohort of patients (n=287, weighing ≤75 kg/165 lbs) were randomized to fixed-dose treatment groups and received four weeks of treatment. Patients were randomized to receive final doses of 10, 20, 30, and 40 mg ADDERALL XR or placebo once daily in the morning. Patients randomized to doses greater than 10 mg were titrated to their final doses by 10 mg each week. The secondary cohort consisted of 40 subjects weighing >75 kg/165 lbs who were randomized to fixed-dose treatment groups receiving final doses of 50 and 60 mg ADDERALL XR or placebo once daily in the morning for 4 weeks. The primary efficacy variable was the Attention Deficit Hyperactivity Disorder-Rating Scale IV (ADHD-RS-IV) total score for the primary cohort. The ADHD-RS-IV is an 18-item scale that measures the core symptoms of ADHD. Improvements in the primary cohort were statistically significantly greater in all four primary cohort active treatment groups (ADDERALL XR 10 mg, 20 mg, 30 mg, and 40 mg) compared with the placebo group. There was not adequate evidence that doses greater than 20 mg/day conferred additional benefit.

Adult Patients

A double-blind, randomized, placebo-controlled, parallel-group study was conducted in adults (N=255) who met DSM-IV® criteria for ADHD. Patients were randomized to fixed-dose treatment groups receiving final doses of 20, 40, or 60 mg of ADDERALL XR or placebo once daily in the morning for four weeks. Significant improvements, measured with the Attention Deficit Hyperactivity Disorder-Rating Scale (ADHD-RS), an 18-item scale that measures the core symptoms of ADHD, were observed at endpoint for all ADDERALL XR doses compared to patients who received placebo for all four weeks. There was not adequate evidence that doses greater than 20 mg/day conferred additional benefit.
Head and neck cancer (HNC) entails a heterogenous neoplastic disease that arises from the mucosal epithelium of the upper respiratory system and the gastrointestinal tract. It is characterized by high morbidity and mortality, being the eighth most common cancer worldwide. It is believed that the mesenchymal/stem stromal cells (MSCs) present in the tumour milieu play a key role in the modulation of tumour initiation, development and patient outcomes; they also influence the resistance to cisplatin-based chemotherapy, the gold standard for advanced HNC. MSCs are multipotent, heterogeneous and mobile cells. Although no MSC-specific markers exist, they can be recognized based on several others, such as CD73, CD90 and CD105, while lacking the presence of CD45, CD34, CD14 or CD11b, CD79α, or CD19 and HLA-DR antigens; they share phenotypic similarity with stromal cells and their capacity to differentiate into other cell types. In the tumour niche, MSC populations are characterized by cell quiescence, self-renewal capacity, low reactive oxygen species production and the acquisition of epithelial-to-mesenchymal transition properties. They may play a key role in the process of acquiring drug resistance and thus in treatment failure. The present narrative review examines the links between MSCs and HNC, as well as the different mechanisms involved in the development of resistance to current chemo-radiotherapies in HNC. It also examines the possibilities of pharmacological targeting of stemness-related chemoresistance in HNSCC. It describes promising new strategies to optimize chemoradiotherapy, with the potential to personalize patient treatment approaches, and highlights future therapeutic perspectives in HNC.
Bempedoic acid

Bempedoic acid was negative for mutagenicity in an in vitro Ames assay and negative for clastogenicity in the vitro human lymphocyte chromosome aberration assay. Bempedoic acid was negative in both in vivo mouse micronucleus and in vivo rat bone marrow micronucleus/liver comet assay. In a 2-year rat carcinogenicity study, Wistar rats were given oral doses of bempedoic acid at 3, 10 and 30 mg/kg/day. An increased incidence of liver hepatocellular adenomas and hepatocellular adenomas combined with carcinomas, thyroid gland follicular cell adenoma and follicular cell adenomas combined with carcinomas, and pancreatic islet cell adenomas combined with carcinomas were observed in male rats at the dose of 30 mg/kg/day (exposure equivalent to the maximum recommended human dose (MRHD), based on AUC). In a 2-year mice carcinogenicity study, CD-1 mice were given oral doses of bempedoic acid at 25, 75 and 150 mg/kg/day. Bempedoic acid-related increases in the incidence of liver hepatocellular adenomas, hepatocellular carcinomas and hepatocellular adenomas combined with carcinomas in male mice were observed at 75 and 150 mg/kg/day (exposures equivalent to the MRHD). Observations of liver and thyroid tumors are consistent with PPAR alpha agonism in rodents. The human relevance of pancreatic islet cell tumor findings is unknown.

In fertility and early embryofetal development study in rats, bempedoic acid was given orally to male and female rats at 10, 30 and 60 mg/kg/day. Males were dosed for 28 days prior to mating and females were dosed 14 days prior to mating through gestation day 7. No adverse effects on fertility were observed in females in the absence of maternal toxicity. No effects were observed on male fertility outcomes, but decreases in sperm counts were observed at 60 mg/kg/day (9 times the MRHD).

Ezetimibe

A 104-week dietary carcinogenicity study with ezetimibe was conducted in rats at doses up to 1,500 mg/kg/day (males) and 500 mg/kg/day (females) (approximately 20 times the human exposure at 10 mg daily based on AUC0-24hr for total ezetimibe). A 104-week dietary carcinogenicity study with ezetimibe was also conducted in mice at doses up to 500 mg/kg/day (>150 times the human exposure at 10 mg daily based on AUC0-24hr for total ezetimibe). There were no statistically significant increases in tumor incidences in drug-treated rats or mice.

No evidence of mutagenicity was observed in vitro in a microbial mutagenicity (Ames) test with Salmonella typhimurium and Escherichia coli with or without metabolic activation. No evidence of clastogenicity was observed in vitro in a chromosomal aberration assay in human peripheral blood lymphocytes with or without metabolic activation. In addition, there was no evidence of genotoxicity in the in vivo mouse micronucleus test.

In oral (gavage) fertility studies of ezetimibe conducted in rats, there was no evidence of reproductive toxicity at doses up to 1,000 mg/kg/day in male or female rats (approximately 7 times the human exposure at 10 mg daily based on AUC0-24hr for total ezetimibe).
Angelman syndrome (AS, MIM #105830) is a neurodevelopmental disorder characterized by severe intellectual disability, profound developmental delay, movement or balance problems, an excessively cheerful disposition, and seizures. AS results from inadequate expression of the maternal UBE3A gene (MIM #601623), which encodes an E3 ligase in the ubiquitin-proteasome pathway. Here we present the case of two sisters with features consistent with AS who had negative methylation analyses. An autism/intellectual disability expanded panel revealed a maternally inherited novel UBE3A (NM_001354506.2) variant c.2443C>T p.(Pro815Ser) in both patients that was initially classified as a variant of uncertain significance. The patients were enrolled in Indiana University's Undiagnosed Rare Disease Clinic (URDC) to further investigate the variant. Additional data, including deep phenotyping, familial segregation analysis, and in silico studies, suggest that the variant is likely pathogenic. 3D modeling studies based on the available crystal structure revealed that the Pro815Ser variant can introduce more flexibility into the protein and alter its enzymatic activity. Recent literature confirms the pathogenic nature of the variant. Reanalysis of the UBE3A variant has heightened existing knowledge of AS and has offered this family an end to their diagnostic odyssey.
The invention relates to a liquid cosmetic powder, which is contained in a container. It includes a color pigment, and an aqueous solvent capable of dissolving the color pigment. The color pigment is implemented as cosmetic powder and the aqueous solvent is implemented by cosmetic solution. The volume ratio of the color pigment to the aqueous solvent is about 1:2. By mixing the color pigment and the aqueous solvent can create cosmetic powder does similar with a cosmetic solution. It is easily applied on skin and keeps skin clean but not oily, especially suitable for oil and mixed type skin.
The invention relates to a traditional Chinese medicine capsule and a matched hot paste for treating secondary hypothyroidism and belongs to the technical field of traditional Chinese medicines. The traditional Chinese medicine capsule is prepared from the following medicines: radix aconiti carmichaeli, rhizoma zingiberis, radix paeoniae alba, cassia twig, bighead atractylodes rhizome, semen cuscutae, fennels, poria cocos, morinda officinalis, rhizoma curculiginis, liquorice, selfheal, radix bupleurim, dandelion, kelps, radix isatidis, curcuma aromatica, radices trichosanthis, spina gleditsiae, fructus forsythiae, scutellaria baicalensis, radix ranunculi ternate and oysters. The matched hot paste is prepared from the following medicines: rhizoma arisaematis, pinellia ternate, radix clematidis, asarum, pseudo-ginseng, sulfur, cinnabar and realgar. The traditional Chinese medicine capsule provided by the invention is highly warm or highly hot, has the functions of warming the meridians and tonifying fire and helping yang as well as tonifying spleen and disinhibiting water and warmly resolving water-dampness, and has the effects of removing stasis, removing swellings and clearing away heat and toxic materials. The kelps have the functions of softening hardness and transforming phlegm and disinhibiting water and reducing heat, and are rich in iodine. Assisted by matched hot paste traditional Chinese medicine powder, a source of heat is benefited for restraining predominant yin by reinforcing yang and inner and outer sides are matched to recuperate under medical treatment, so that a satisfactory curative effect is obtained.
PURPOSE OF REVIEW: It is estimated that approximately a third of patients undergoing certain surgeries may report some degree of persistent pain postoperatively. Chronic postsurgical pain (CPSP) reduces quality of life, is challenging to treat, and has significant socio-economic impact.
RECENT FINDINGS: From an epidemiological perspective, factors that predispose patients to the development of CPSP may be considered in relation to the patient, the procedure or, the care environment. Prevention or management of transition from acute to chronic pain often need a multidisciplinary approach beginning early in the preoperative period and continuing beyond surgical admission. The current concepts regarding the role of central and peripheral nervous systems in chronification of pain may provide targets for future therapies but, the current evidence seems to suggest that a multimodal analgesic approach of preventive analgesia along with a continued follow-up and treatment after hospital discharge may hold the key to identify and manage the transitioning of acute to chronic pain.
SUMMARY: A comprehensive multidisciplinary approach with prior identification of risk factors, minimizing the surgical insult and a culture of utilizing multimodal analgesia and continued surveillance beyond the period of hospitalization is an important step towards reducing the development of chronic pain. A transitional pain service model may accomplish many of these goals.
PROBLEM TO BE SOLVED: To obtain the subject composition excellent in stability of product, taste and water dispersibility and solubility by adding a cyclodextrin compound to an araliaceous ginseng extract. SOLUTION: This composition comprises (A) an araliaceous ginseng extract and (B) a cyclodextrin compound (e.g. α-cyclodextrin). The component A is pref. exemplified by a Denshichi ginseng extract or Panax ginseng extract. When a combination of these ginsengs is used, 0.3 to 3 pts.wt. of Panax ginseng extract is pref. used based on 1 pts.wt. of Denshichi ginseng extract. It is pref. to use 0.2 to 10 pts.wt. of component B based on 1 pts.wt. of the solid component of the component A. The composition takes pref. a granular form whose size is pref. 42 to 16 mesh (355 μm to 1 mm). The granular composition is obtained by mixing a solution of the component A with powder or granules of the component B and then granulating the resultant mixture while drying it.
There is an increasing body of evidence suggesting that a single exposure to certain chemicals can have transgenerational effects, with the underlying mechanism believed to be epigenetic. However, it remains largely unknown whether psychiatric conditions like ADHD or autism, induced by environmental chemicals, can be inherited across generations. Pregnant rats were purchased from a commercial breeder. On the 7th day of gestation (E7), they were divided into two groups: one group was orally exposed to silver nanoparticles (AgNP; 4 mg/kg), while the control group received vehicle alone. The subsequent generation (F1) underwent spontaneous motor activity (SMA) measurements at 8-11 weeks of age. For breeding at 26 weeks of age, rats with higher SMA were selected from hyperactive litters, while untreated rats were randomly selected. This process was continued for four generations in both groups. The AgNP-primed rats at 4th generation displayed significantly higher SMA, 1.8 times greater than that of untreated rats. Intraperitoneal injection of valproic acid (150 mg/kg), an epigenetic modifier to 5-day-old rats causes adult hyperactivity (1.4-fold), suggesting that epigenetic modification contributes to rat hyperactivity. Global DNA methylation profiles in the mesencephalon were positively correlated in both groups of hyperactive rats. Furthermore, there were 7-8 common genes showing both hypermethylation and hypomethylation, which are involved in neuronal development, neuronal function, transcriptional activity, DNA binding activity, cell differentiation, ubiquitination processes, or histone modification, including Pax 6 and Mecp 2. Thus, it is most likely that rats retain hyperactivity through mesencephalic DNA methylation status across transgeneration.
The study will be a multicenter, prospective, open-label, blinded-endpoint randomized controlled trial (2 arms with 1:1 randomization). Participants with acute minor ischemic stroke (baseline NIHSS≤5) within 12 hours of symptoms onset (symptom onset is defined by the "last seen normal" principle for wake-up stroke) accompanied with measurable neurological deficit and DWI/FLAIR mismatch will be enrolled. The measurable neurological deficit is defined as impairment of language or motor function. Participants will be randomized into 2 groups: Intervention group (rhTNK-tPA): 0.25mg/kg, the maximum dose does not exceed 25mg. Control group: Standard medical care according to the guideline. The primary endpoint is excellent functional outcome (Modified Rankin Scale score, mRS 0-1) at 90-day.